Adherence to 6-Mercaptopurine (6-MP), Habit Strength, and Health-related
Quality of Life in Pediatric Acute Lymphoblastic Leukemia (ALL): A Mixed
Methods Study
Abstract
Background: Low 6-mercaptopurine (6-MP) adherence
(<95%) is associated with increased relapse in pediatric acute
lymphoblastic leukemia (ALL). Stronger habit has been associated with
higher adherence. Our objective was to examine the relationship of 6-MP
adherence to habit strength and health-related quality of life (HRQOL)
in children with ALL. Methods: A single-center, cross-sectional
study of 52 participants: 11 patients (mean age 16±4, 45% Female) and
41 parents/caregivers (age 37±5, 80% Female). Participants completed
Visual Analogue Scale (VAS dose), Patient Reported
Outcomes Measurement Information System (PROMIS) Medication Adherence
Scale (PMAS), Self-Regulated Habit Index (SRHI), and PROMIS HRQoL
measures. Descriptive statistics and spearman’s rho correlations were
used. Eleven semi-structured interviews of participants were conducted
and analyzed using Grounded Theory and thematic analysis.
Results: Overall, 81% (42/52) of participants reported high
6-MP adherence (VAS dose ≥95%): patients 91% (10/11)
and parents 78% (32/41). Higher adherence was correlated with better
peer relationship scores (r s=0.34, P=0.03). No
significant correlation was found between adherence and habit strength.
Reported facilitators for higher 6-MP included reminders, care team
communications, developing personalized tools, experience with
medication administration, self-efficacy, and access to social support.
On the other hand, financial burden, scheduling conflicts, and
medication access were common barriers cited by participants.
Conclusions: One-fifth of participants reported low 6-MP
adherence, and habit strength wasn’t associated with adherence rates.
Variability of 6-MP routines over treatment may prohibit automaticity.
Behavioral interventions aimed at promoting habit formation could
address barriers to 6-MP adherence and improve health outcomes in
pediatric ALL.